Sanford Burnham team sees promise in new melanoma drug

Scientists at Sanford Burnham Prebys Medical Discovery Institute say that a new molecular machinery-targeting drug dubbed SBI-756 demonstrated preclinical evidence of success in a mouse model for melanoma.

Fruit flies may provide a biomarker for early-onset Parkinson's

After studying the visual responses of fruit flies with different types of Parkinson's disease, biologists at the University of York believe they may be on to a new biomarker that could be used to detect the early-onset form of the disease.

U.K. investigators publish small, promising study of Victoza for NASH

Investigators at the University of Birmingham in the U.K. have published the results of a small but intriguing study that has highlighted the potential of Novo Nordisk's blockbuster diabetes drug Victoza (liraglutide) for NASH, an increasingly common liver disease.

Arno's HDAC inhibitor looks promising in preclinical cachexia study as cash runs low

Investigators at The Ohio State University Comprehensive Cancer Center say they've nailed down fresh preclinical evidence that an experimental HDAC inhibitor can guard against muscle wasting in cancer cases.

Mount Sinai team maps a key combo role for new checkpoint drugs

A new mouse study conducted by scientists at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai has pointed to another way that checkpoint inhibitors can play an important part of a combination therapy in attacking cancer.

Berkeley lab develops a new nanocarrier that targets glioblastoma

Nanocarriers are microscopic synthetic particles that can deliver therapeutic drugs to a required area in the body. Now researchers say they have developed a new class of nanocarriers, prompting optimism in the long fight against aggressive cases of glioblastoma multiforme.

Emory team links inflammation to a third of all cases of depression

Researchers say that persistent and high inflammation in the brain affects connections relating to important symptoms that are currently difficult to treat, triggering up to a third of all cases of depression. And they believe their discovery can point to other therapeutic remedies for depression

Bone microenvironment offers new approach on prostate cancer

Studying the bone microenvironment may offer new insights into better drugs for fighting prostate cancer metastasis.

CRISPR/Cas9 2.0: Research team offers an upgrade to gene editing tech

A group of RNA experts say they've developed a potential upgrade for the wildly popular CRISPR/Cas9 gene editing tech that has been picked up in labs around the world.

UCSD team targeting new stress pathway in Alzheimer's program

Despite repeated assurances from rival camps that toxic loads of amyloid beta and tau are likely causes of Alzheimer's disease, no one is quite sure what is going on and clinical failures are routine. But investigators at UC San Diego School of Medicine say they have been garnering some preclinical clues that would suggest there could be a new pathway to follow in the clinic.

Generic alcoholism drug used to flush dormant HIV

Actually eradicating the virus that causes AIDS has been thwarted by the virus' ability to hide out in dormant cells. Now researchers say that a generic alcoholism drug called disulfiram has demonstrated the ability to wake up the virus and flush it out for destruction.

GC-1 drug shifts bad 'white' fat into good, calorie-burning 'brown' fat in mice

Researchers at Baylor College of Medicine have published animal research that provides some proof that an experimental drug could one day provide a new therapeutic to effectively fight fat by pushing "bad" white fat to become "good" brown fat.

UNC scientists develop a new way to prod stem cells into bone

A team led by Janet Rubin at the University of North Carolina School of Medicine recently found a novel method to push stem cells into forming bone.

MD Anderson group tracks 'modest' impact of lymphoma drug

One of Takeda's experimental cancer therapies has been tested in a small group of advanced lymphoma patients, offering a snapshot of "modest" efficacy that could be amplified in earlier stage patients and in combination with other drugs.

Warp Drive Bio constructs a new cancer R&D tech platform

Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers.

Microbiome study highlights bacterial strategy for treating severe diarrhea

After sequencing the DNA of patients suffering from severe diarrhea and their healthy relatives, researchers at Michigan State say they have identified a new microbiome strategy for aiding patients by better balancing levels of healthy and sickening gut bacteria.

KIT team points pancreatic cancer therapy toward clinical trials

Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor tyrosine kinases like MET and VEGFR-2 that drive pancreatic cancer, a group of German investigators say they've successfully tested a new peptide approach in mice that throws up a hurdle that can blunt and perhaps even stop the development of the disease.

Case Western researchers spotlight role of rapid protein movement in hearing loss

Researchers at Case Western Reserve University School of Medicine have drawn an interesting link between the movement of protein in hair bundles and the signs of the repair and renewal mechanism. These findings hold promise in furthering our knowledge of the molecular changes in hearing loss, which could lead to new therapies in the clinic.

Washington investigators develop a new tool for high-res live cancer imaging

Researchers have combined the use of a nonfluorescent bacterial phytochrome with photoacoustic tomography imaging in cancerous tissue, resulting in high spatial resolution, increased penetration depth, and crucially, enhanced detection sensitivity with significantly reduced background signals.

JAK inhibitors target senescent cells in aging study

Researchers at the Mayo Clinic say that inhibiting certain enzyme pathways in cells cut down on inflammation and reduced frailty, a pathway that could play a significant role in antiaging therapies.